The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.
C1 inhibitor
DELPHI
disease control
guideline
hereditary angioedema
management
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
22
11
2021
received:
16
09
2021
accepted:
08
12
2021
pubmed:
11
1
2022
medline:
2
7
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.
Substances chimiques
Complement C1 Inhibitor Protein
0
Types de publication
Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1961-1990Informations de copyright
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: two genetic variants. Science. 1965;148(3672):957-958.
Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C' 1-Esterase. Am J Med. 1963;35:37-44.
Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351(9117):1693-1697.
Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575-1596.
Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update. World Allergy Organization J. 2018;11:5.
Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol. 2004;114(3):629-637.
Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30-S40.
Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):22.
Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011;21(5):333-347. quiz follow 347.
Caballero T, Baeza ML, Cabanas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011;21(6):422-441; quiz 442-423.
Giavina-Bianchi P, Franca AT, Grumach AS, et al. Brazilian guidelines for the diagnosis and treatment of hereditary angioedema. Clinics (Sao Paulo). 2011;66(9):1627-1636.
Brozek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588-595. https://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2010.02530.x
Jindal AK, Reshef A, Longhurst H, workgroup G. Mitigating disparity in health-care resources between countries for management of hereditary angioedema. Clin Rev Allergy Immunol. 2021;61(1):84-97.
Dalkey N. Experimental study of group opinion - Delphi method. Futures. 1969;1(5):408-426. https://doi.org/10.1016/S0016-3287(69)80025-X
Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401-409.
Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267-274.
Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci. 1982;284(1):2-9.
Dinkelacker E. Ueber acutes Oedem. Doctoral thesis. Medicinische Facultät zu Kiel; 1882.
Rosen FS, Austen KF. The "neurotic edema" (hereditary angioedema). N Engl J Med. 1969;280(24):1356-1357.
Zuraw BL, Christiansen SC. Pathophysiology of hereditary angioedema. Am J Rhinol Allergy. 2011;25(6):373-378.
Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602-616.
Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53(3):373-388; quiz 389-392.
Maurer M, Magerl M. Differences and similarities in the mechanisms and clinical expression of Bradykinin-mediated vs. mast cell-mediated angioedema. Clin Rev Allergy Immunol. 2021;61(1):40-49.
Schulkes KJ, Van den Elzen MT, Hack EC, Otten HG, Bruijnzeel-Koomen CA, Knulst AC. Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study. Clin Transl Allergy. 2015;5(1):5.
Can PK, Degi Rmentepe EN, Etikan P, et al. Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. World Allergy Organ J. 2021;14(7):100554.
Obtulowicz K. Bradykinin-mediated angioedema. Pol Arch Med Wewn. 2016;126(1-2):76-85.
Cicardi M, Zuraw BL. Angioedema due to bradykinin dysregulation. J Allergy Clin Immunol Pract. 2018;6(4):1132-1141.
Lepelley M, Bernardeau C, Defendi F, Crochet J, Mallaret M, Bouillet L. Update on bradykinin-mediated angioedema in 2020. Therapie. 2020;75(2):195-205.
Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213-217.
Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Comm. 2006;343(4):1286-1289.
Bafunno V, Firinu D, D'Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immun. 2018;141(3):1009-1017.
Bork K, Wulff K, Steinmuller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73(2):442-450.
Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy. 2019;74(12):2479-2481.
Ariano A, D'Apolito M, Bova M, et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy. 2020;75(11):2989-2992.
Bork K, Wulff K, Mohl BS, et al. Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. J Allergy Clin Immunol. 2021;148(4):1041-1048.
Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15(1):289.
Magerl M, Germenis AE, Maas C, Maurer M. Hereditary angioedema with normal C1 inhibitor: update on evaluation and treatment. Immunol Allergy Clin North Am. 2017;37(3):571-584.
Sobotkova M, Zachova R, Hakl R, et al. Acquired angioedema with C1 inhibitor deficiency: occurrence, clinical features, and management: a nationwide retrospective study in the Czech Republic patients. Int Arch Allergy Immunol. 2021;182(7):642-649.
Caldwell JR, Ruddy S, Schur PH, Austen KF. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39-52.
Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol. 1997;136(2):153-158.
Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature. J Clin Hypertens (Greenwich). 2017;19(12):1377-1382.
Rasmussen ER, von Buchwald C, Wadelius M, et al. Assessment of 105 patients with angiotensin converting enzyme-inhibitor induced angioedema. Int J Otolaryngol. 2017;2017:1476402.
Zanichelli A, Azin GM, Wu MA, et al. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2017;5(5):1307-1313.
Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161(5):1153-1158.
Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis. 2015;10:11.
Aygoren-Pursun E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.
Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S08-S13.
Germenis AE, Speletas M. Genetics of hereditary angioedema revisited. Clin Rev Allergy Immunol. 2016;51(2):170-182.
Ponard D, Gaboriaud C, Charignon D, et al. SERPING1 mutation update: mutation spectrum and C1 Inhibitor phenotypes. Hum Mutat. 2020;41(1):38-57.
Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106(6):1147-1154.
Proper SP, Lavery WJ, Bernstein JA. Definition and classification of hereditary angioedema. Allergy Asthma Proc. 2020;41(Suppl 1):S03-S07.
Guryanova I, Suffritti C, Parolin D, et al. Hereditary angioedema due to C1 inhibitor deficiency in Belarus: epidemiology, access to diagnosis and seven novel mutations in SERPING1 gene. Clin Mol Allergy. 2021;19(1):3.
Kaplan AP, Joseph K. Complement, kinins, and hereditary angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol. 2016;51(2):207-215.
de Maat S, Joseph K, Maas C, Kaplan AP. Blood clotting and the pathogenesis of types I and II hereditary angioedema. Clin Rev Allergy Immunol. 2021;60(3):348-356.
De Maat S, Hofman ZLM, Maas C. Hereditary angioedema: the plasma contact system out of control. J Thromb Haemost. 2018;16(9):1674-1685.
Donaldson VH, Rosen FS, Bing DH. Kinin generation in hereditary angioneurotic edema (H.A.N.E.) plasma. Adv Exp Med Biol. 1983;156:183-191.
Jacques L, Couture R, Drapeau G, Regoli D. Capillary permeability induced by intravenous neurokinins. Receptor characterization and mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(2):170-179.
Whalley ET, Amure YO, Lye RH. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1987;335(4):433-437.
Whalley ET, Nwator IA, Stewart JM, Vavrek RJ. Analysis of the receptors mediating vascular actions of bradykinin. Naunyn Schmiedebergs Arch Pharmacol. 1987;336(4):430-433.
Maas C, Lopez-Lera A. Hereditary angioedema: insights into inflammation and allergy. Mol Immunol. 2019;112:378-386.
Bork K, Wulff K, Witzke G, Hardt J. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). Allergy. 2017;72(2):320-324.
Bork K, Wulff K, Witzke G, Machnig T, Hardt J. Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene. Orphanet J Rare Dis. 2020;15(1):52.
Cicardi M, Zanichelli A. Diagnosing angioedema. Immunol Allergy Clin North Am. 2013;33(4):449-456.
Nowicki RJ, Grubska-Suchanek E, Porebski G, et al. Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA). Postepy Dermatol Alergol. 2020;37(4):445-451.
Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol. 2004;57(2):213-214.
Tarzi MD, Hickey A, Forster T, Mohammadi M, Longhurst HJ. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol. 2007;149(3):513-516.
Wagenaar-Bos IG, Drouet C, Aygoren-Pursun E, et al. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods. 2008;338(1-2):14-20.
Aabom A, Bygum A, Koch C. Complement factor C4 activation in patients with hereditary angioedema. Clin Biochem. 2017;50(15):816-821.
Pedrosa M, Phillips-Angles E, Lopez-Lera A, Lopez-Trascasa M, Caballero T. Complement study versus CINH gene testing for the diagnosis of type I hereditary angioedema in children. J Clin Immunol. 2016;36(1):16-18.
Lai Y, Zhang G, Inhaber N, et al. A robust multiplexed assay to quantify C1-inhibitor, C1q, and C4 proteins for in vitro diagnosis of hereditary angioedema from dried blood spot. J Pharm Biomed Anal. 2021;195:113844.
Germenis AE, Margaglione M, Pesquero JB, et al. International consensus on the use of genetics in the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2020;8(3):901-911.
Ebo DG, Van Gasse AL, Sabato V, et al. Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism. J Allergy Clin Immunol Pract. 2018;6(1):277-279 e271.
Buttgereit T, Maurer M. Classification and pathophysiology of angioedema. Hautarzt. 2019;70(2):84-91.
Loules G, Parsopoulou F, Zamanakou M, et al. Deciphering the genetics of primary angioedema with normal levels of C1 inhibitor. J Clin Med. 2020;9(11):3402.
Emelyanov AV, Leshenkova EV, Kameneva GA. Diagnosis and treatment of hereditary angioedema with normal C1-inhibitor level. Ter Arkh. 2020;92(12):86-90.
Polai Z, Balla Z, Andrasi N, et al. A follow-up survey of patients with acquired angioedema due to C1-inhibitor deficiency. J Intern Med. 2021;289(4):547-558.
Gobert D, Bouillet L, Armengol G, et al. Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment. Rev Med Interne. 2020;41(12):838-842.
Gobert D, Paule R, Ponard D, et al. A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients. Medicine (Baltimore). 2016;95(33):e4363.
Bork K, Staubach-Renz P, Hardt J. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate. Orphanet J Rare Dis. 2019;14(1):65.
Balla Z, Zsilinszky Z, Polai Z, et al. The importance of complement testing in acquired angioedema related to angiotensin-converting enzyme inhibitors. J Allergy Clin Immunol Pract. 2021;9(2):947-955.
Bas M, Greve J, Strassen U, Khosravani F, Hoffmann TK, Kojda G. Angioedema induced by cardiovascular drugs: new players join old friends. Allergy. 2015;70(10):1196-1200.
Bouillet L, Boccon-Gibod I, Ponard D, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103(5):448.
Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. Allergy. 2020;75(6):1394-1403.
Magerl M, Bader M, Gompel A, et al. Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012, Berlin 23-24 August 2012. Inflamm Res. 2014;63(3):173-178.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.
Rasmussen ER, de Freitas PV, Bygum A. Urticaria and prodromal symptoms including erythema marginatum in Danish patients with hereditary angioedema. Acta Derm Venereol. 2016;96(3):373-376.
Tadros S, Hayman GR. Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema. Ann Allergy Asthma Immunol. 2019;122(6):666-667.
Martin L, Renne T, Drouet C. Urticaria as a presenting prodromal manifestation of attacks of hereditary angioedema. Acta Derm Venereol. 2016;96(4):574-575.
Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria. Allergy. 2019;74(12):2550-2553.
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277.
Peveling-Oberhag A, Reimann H, Weyer V, Goloborodko E, Staubach P. High-concentration liquid prednisolone formula: filling a therapeutic niche in severe acute attacks of Urticaria and Angioedema. Skin Pharmacol Physiol. 2016;29(1):9-12.
Santa C, Valente CL, Mesquita M, et al. Acute urticaria in children: from pediatric emergency department to allergology consultation at a central hospital. Eur Ann Allergy Clin Immunol. 2021. Online ahead of print.
Rajan N, Sharma V, Patro SK, Goyal A. Acute presentation of undiagnosed hereditary angioedema of the larynx: averting death. Turk Arch Otorhinolaryngol. 2020;58(4):279-281.
Piotrowicz-Wojcik K, Porebski G. Life-threatening laryngeal attacks in hereditary angioedema patients. Otolaryngol Pol. 2020;74(2):1-5.
Moldovan D, Bara N, Nadasan V, Gabos G, Mihaly E. Consequences of misdiagnosed and mismanaged hereditary angioedema laryngeal attacks: an overview of cases from the Romanian registry. Case Rep Emerg Med. 2018;2018:6363787.
Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692-697.
Gutierrez M, Veronez CL, Rodrigues Valle SO, et al. Unnecessary abdominal surgeries in attacks of hereditary angioedema with normal C1 inhibitor. Clin Rev Allergy Immunol. 2021;61(1):60-65.
Poza Cordón J, de María Pallarés P, Caballero Molina T. Ultrasound findings in an abdominal crisis of a patient with hereditary angioedema. Rev Esp Enferm Dig. 2020;112(5):418.
Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619-627.
Kusuma A, Relan A, Knulst AC, et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med. 2012;125(9):937 e917-924.
Christiansen SC, Bygum A, Banerji A, et al. Before and after, the impact of available on-demand treatment for HAE. Allergy Asthma Proc. 2015;36(2):145-150.
Zanichelli A, Mansi M, Azin GM, et al. Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency. Allergy. 2015;70(12):1553-1558.
Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161(5):714-718.
Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010;30(6):823-829.
Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;110(3):184-188 e182.
Banta E, Horn P, Craig TJ. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. Allergy Asthma Proc. 2011;32(4):319-324.
Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy. 2011;66(12):1604-1611.
Craig TJ, Rojavin MA, Machnig T, Keinecke HO, Bernstein JA. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;111(3):211-215.
Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013;8(2):e53773.
Hernández Fernandez de Rojas D, Ibañez E, Longhurst H, et al. Treatment of HAE attacks in the Icatibant outcome survey: an analysis of Icatibant self-administration versus administration by Health Care Professionals. Int Arch Allergy Immunol. 2015;167(1):21-28.
Leibovich-Nassi I, Golander H, Somech R, Har-Even D, Reshef A. New instrument for the evaluation of prodromes and attacks of hereditary angioedema (HAE-EPA). Clin Rev Allergy Immunol. 2021;61(1):29-39.
Leibovich-Nassi I, Reshef A. The enigma of prodromes in hereditary angioedema (HAE). Clin Rev Allergy Immunol. 2021;61(1):15-28.
Magerl M, Doumoulakis G, Kalkounou I, et al. Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clin Exp Dermatol. 2014;39(3):298-303.
Prematta MJ, Bewtra AK, Levy RJ, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther. 2012;29(10):913-922.
Shire. Cinryze prescribing information. 2021. http://pi.shirecontent.com/PI/PDFs/Cinryze_USA_ENG.pdf. Accessed August 16, 2021.
CSL Behring. Berinert 500 prescribing information. 2021. http://cslbehring.vo.llnwd.net/o33/u/central/PI/US/Berinert/EN/Berinert-Prescribing-Information.pdf. Accessed August 16, 2021.
Takeda. Kalbitor prescribing information. 2020. https://www.shirecontent.com/PI/PDFs/Kalbitor_USA_ENG.pdf. Accessed August 16, 2021.
PharmingGroup. Ruconest prescribing information. 2020. https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf. Accessed August 16, 2021.
Takeda. Prescribing information icatibant. 2021. https://www.shirecontent.com/PI/PDFs/Firazyr_USA_ENG.pdf. Accessed August 16, 2021.
Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541.
Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808.
Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523-529.
Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163-169. e161.
Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-827 e814.
Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513-522.
Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract. 2005;59(5):594-599.
Wentzel N, Panieri A, Ayazi M, et al. Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran. World Allergy Organ J. 2019;12(9):100049.
Sabeen Ahmed A, Fayyaz S. Novel use of Fresh Frozen plasma in treating hereditary angioedema: a success story from Pakistan. Cureus. 2020;12(8):e9669.
Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011;66(2):192-196.
Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998;38(6):540-549.
Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334(25):1630-1634.
Schulz KH. Hereditary Quincke's edema. New therapeutic ways. Hautarzt. 1974;25(1):12-16.
Bernstein JA, Ritchie B, Levy RJ, et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010;105(2):149-154.
Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014;54(6):1552-1561.
Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, von Hentig N, Klingebiel T, Kreuz W. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion. 2010;50(2):354-360.
Brackertz D, Isler E, Kueppers F. Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin Allergy. 1975;5(1):89-94.
Hofstra JJ, Budde IK, van Twuyver E, et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor(R)): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol. 2012;142(3):280-290.
De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com. Transfus Apher Sci. 2003;29(3):247-254.
Gröner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion. 2012;52(10):2104-2112.
Simon TL, Kalina U, Laske R, Mycroft S, Widmer E, Roth NJ. Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema. Allergy Asthma Proc. 2020;41(2):99-107.
Terpstra FG, Kleijn M, Koenderman AH, et al. Viral safety of C1-inhibitor NF. Biologicals. 2007;35(3):173-181.
Reshef A, Grivcheva-Panovska V, Kessel A, et al. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatr Allergy Immunol. 2019;30(5):562-568.
Farrell C, Hayes S, Relan A, van Amersfoort ES, Pijpstra R, Hack CE. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol. 2013;76(6):897-907.
van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116(4):876-883.
van Veen HA, Koiter J, Vogelezang CJ, et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol. 2012;162(2-3):319-326.
Moldovan D, Bernstein JA, Cicardi M. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy. 2015;7(7):739-752.
Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: european open-label extension study. Clin Exp Allergy. 2012;42(6):929-935.
Riedl M. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. Clin Drug Investig. 2015;35(7):407-417.
DyaxCorp. Withdrawal of Kalbitor at EMA. 2011.
Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523-531.
Craig TJ, Li HH, Riedl M, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(2):206-212. e204.
Antonio A, Rocha ESM. Coronary vasodilation produced by bradykinin on isolated mammalian heart. Circ Res. 1962;11:910-915.
Erikson U. Peripheral arteriography during Bradykinin induced vasodilation. Acta Radiol Diagn (Stockh). 1965;3:193-201.
Rocha ESM, Beraldo WT, Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol. 1949;156(2):261-273.
Longhurst HJ, Aberer W, Bouillet L, et al. Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey. Allergy Asthma Proc. 2015;36(5):399-406.
Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119(6):1497-1503.
Farkas H. Icatibant as acute treatment for hereditary angioedema in adults. Expert Rev Clin Pharmacol. 2016;9(6):779-788.
Farkas H, Kőhalmi KV. Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years. Expert Rev Clin Immunol. 2018;14(6):447-460.
Bork K, Bernstein JA, Machnig T, Craig TJ. Efficacy of different medical therapies for the treatment of acute laryngeal attacks of hereditary angioedema due to C1-esterase inhibitor deficiency. J Emerg Med. 2016;50(4):567-580 e561.
Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75(4):349-354.
Javaud N, Gompel A, Bouillet L, et al. Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. Annals Allergy Asthma Immunol. 2015;114(6):499-503.
Aygoren-Pursun E, Martinez Saguer I, Kreuz W, Klingebiel T, Schwabe D. Risk of angioedema following invasive or surgical procedures in HAE type I and II-the natural history. Allergy. 2013;68(8):1034-1039.
Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc. 2003;134(8):1088-1094.
Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):58-64.
Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor-a long-term survey. Allergy. 2012;67(12):1586-1593.
Forrest A, Milne N, Soon A. Hereditary angioedema: death after a dental extraction. Aust Dent J. 2017;62(1):107-110.
Nanda MK, Singh U, Wilmot J, Bernstein JA. A cross-sectional questionnaire assessing patient and physician use of short-term prophylaxis for hereditary angioedema. Annals Allergy Asthma Immunol. 2014;113(2):198-203.
Farkas H, Gyeney L, Gidofalvy E, Fust G, Varga L. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg. 1999;57(4):404-408.
Magerl M, Frank M, Lumry W, et al. Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: findings from an international patient registry. Ann Allergy Asthma Immunol. 2017;118(1):110-112.
Valerieva A, Staevska M, Jesenak M, et al. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2020;8(2):799-802.
Bernstein JA, Coleman S, Bonnin AJ. Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema. J Cardiothorac Surgery. 2010;5:86.
Ajewole O, Lanlokun M, Dimanche S, Craig T. Short-term prophylaxis for children and adolescents with hereditary angioedema. Allergy Asthma Proc. 2021;42(3):205-213.
Bowen T. Hereditary angioedema consensus 2010. Allergy Asthma Clin Immunol. 2010;6(1):13.
Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379-394.
Betschel S, Badiou J, Binkley K, et al. The International/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2019;15:72.
Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150 e133.
Maurer M, Aygoren-Pursun E, Banerji A, et al. Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. J Allergy Clin Immunol. 2021;148(6):1526-1532.
Kuman Tuncel O, Gokmen NM, Demir E, Gulbahar O, Pirildar S. The impact of hereditary angioedema on quality of life and family planning decisions. Int J Psychiatry Med. 2019;54(6):377-394.
Lumry WR, Weller K, Magerl M, et al. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy. 2021;76(4):1188-1198.
Nicolas A, Launay D, Duprez C, et al. Impact de l’angiœdème héréditaire sur les activités de la vie quotidienne, la sphère émotionnelle et la qualité de vie des patientsImpact of disease on daily activities, emotions and quality of life of patients with hereditary angioedema. Impact of disease on daily activities, emotions and quality of life of patients with hereditary angioedema. Rev Med Interne. 2021;42(9):608-615.
Lumry WR, Zuraw B, Cicardi M, et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021;16(1):86.
Lumry WR, Miller DP, Newcomer S, Fitts D, Dayno J. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy Asthma Proc. 2014;35(5):371-376.
Brix ATH, Boysen HB, Weller K, Caballero T, Bygum A. Patient-reported outcome measures for angioedema: a literature review. Acta Derm Venereol. 2021;101(5):adv00456.
Caballero T, Prior N. Burden of illness and quality-of-life measures in angioedema conditions. Immunol Allergy Clin North Am. 2017;37(3):597-616.
Forjaz MJ, Ayala A, Caminoa M, et al. HAE-AS: a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. J Investig Allergol Clin Immunol. 2021;31(3):246-252.
Prior N, Remor E, Gomez-Traseira C, et al. Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes. 2012;10:82.
Prior N, Remor E, Perez-Fernandez E, et al. Psychometric field study of hereditary angioedema quality of life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract. 2016;4(3):464-473 e464.
Weller K, Donoso T, Magerl M, et al. Development of the angioedema control test-A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy. 2020;75(5):1165-1177.
Weller K, Donoso T, Magerl M, et al. Validation of the angioedema control test (AECT)-A patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract. 2020;8(6):2050-2057 e2054.
Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289-1298.
Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score. Allergy. 2013;68(9):1185-1192.
Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M. The angioedema quality of life questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016;71(8):1203-1209.
Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600-607.
Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
Buttgereit T, Vera C, Weller K, et al. Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study. J Allergy Clin Immunol Pract. 2021;9(10):3744-3751.
Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793-1802 e1792.
Hahn J, Trainotti S, Wigand MC, Schuler PJ, Hoffmann TK, Greve J. Prospective analysis in patients with HAE under prophylaxis with lanadelumab: a real-life experience. J Drugs Dermatol. 2020;19(10):978-983.
Henry Li H, Riedl M, Kashkin J. Update on the use of C1-esterase inhibitor replacement therapy in the acute and prophylactic treatment of hereditary angioedema. Clin Rev Allergy Immunol. 2019;56(2):207-218.
Li HH, Zuraw B, Longhurst HJ, et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. Allergy Asthma Clin Immunol. 2019;15:49.
Zarnowski J, Rabe M, Kage P, Simon JC, Treudler R. Prophylactic treatment in hereditary angioedema is associated with reduced anxiety in patients in Leipzig, Germany. Int Arch Allergy Immunol. 2021;182:1-8.
Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs Context. 2019;8:212605.
Aberer W, Maurer M, Bouillet L, et al. Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Allergy Asthma Clin Immunol. 2017;13:31.
Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study. Allergy. 2022;77(3):979-990.
Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140.
Wedner HJ, Aygoren-Pursun E, Bernstein J, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (Part 2). J Allergy Clin Immunol Pract. 2021;9(6):2305-2314. e2304.
Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164-172. e169.
Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J. 2012;5(12):182-199.
Frank MM. Update on preventive therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin North Am. 2013;33(4):495-503.
Greve J, Strassen U, Gorczyza M, et al. Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. J Dtsch Dermatol Ges. 2016;14(3):266-275.
Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J Dtsch Dermatol Ges. 2011;9(2):99-107.
Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10(1):50.
Aygoren-Pursun E, Soteres DF, Nieto-Martinez SA, et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatr Allergy Immunol. 2019;30(5):553-561.
Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr. 2013;162(5):1017-1022. e1011-1012.
Lumry WR, Martinez-Saguer I, Yang WH, et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. J Allergy Clin Immunol Pract. 2019;7(5):1610-1618. e1614.
Zuraw BL, Cicardi M, Longhurst HJ, et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015;70(10):1319-1328.
Bernstein JA, Manning ME, Li H, et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2014;2(1):77-84.
Giardino F, Cicardi M, Neri S. Use of subcutaneous-C1 INH for acute therapy and prophylaxis of a child with HAE. Pediatr Allergy Immunol. 2015;26(3):296-297.
Kruger R, Dahlinger N, Magerl M, von Bernuth H, Wahn V. Daily subcutaneous administration of human C1 inhibitor in a child with hereditary angioedema type 1. Pediatr Allergy Immunol. 2016;27(2):223-224.
Weller K, Kruger R, Maurer M, Magerl M. Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema. Clin Exp Dermatol. 2016;41(1):91-93.
Lumry WR, Craig T, Zuraw B, et al. Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract. 2018;6(5):1733-1741. e1733.
Andarawewa S, Aygoren-Pursun E. Subcutaneous C1-Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1-INH-HAE. Clin Case Rep. 2021;9(3):1273-1275.
Weller K, Maurer M, Fridman M, Supina D, Schranz J, Magerl M. Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy Asthma Proc. 2017;38(2):143-151.
Bernstein JA, Li HH, Craig TJ, et al. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. Allergy Asthma Clin Immunol. 2019;15:13.
Hahn J, Nordmann-Kleiner M, Trainotti S, Hoffmann TK, Greve J. Successful long-term prophylactic treatment with subcutaneous C1 esterase inhibitor in a patient with hereditary angioedema. J Pharm Pract. 2020;33(6):907-911.
Craig T, Busse P, Gower RG, et al. Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. Ann Allergy Asthma Immunol. 2018;121(6):673-679.
Rasmussen ER, Aagaard L, Bygum A. Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: effectiveness and cost. Ann Allergy Asthma Immunol. 2016;116(5):476-477.
Arzneimittelkommission der deutschen Ärzteschaft. Schwerwiegende thrombenbildung nach Berinert® HS. Deutsches Ärzteblatt. 2000;97(15):A-1016.
Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014;35(6):444-453.
Farkas H, Kohalmi KV, Veszeli N, Zotter Z, Varnai K, Varga L. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc. 2016;37(2):164-170.
Kalaria S, Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc. 2013;34(6):519-522.
Riedl MA, Bygum A, Lumry W, et al. Safety and usage of C1-inhibitor in hereditary angioedema: berinert registry data. J Allergy Clin Immunol Pract. 2016;4(5):963-971.
Burnham K, Reinert JP. Thromboembolic risk of C1 esterase inhibitors: a systematic review on current evidence. Expert Rev Clin Pharmacol. 2020;13(7):779-786.
Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med. 2009;122(8):780-783.
Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376(8):717-728.
Chyung Y, Vince B, Iarrobino R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113(4):460-466. e462.
Riedl MA, Maurer M, Bernstein JA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020;75(11):2879-2887.
Takeda. Prescribing Information Lanadelumab 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro. Accessed August 21, 2021.
Ohsawa I, Honda D, Suzuki Y, et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy. 2021;76(6):1789-1799.
Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med. 2018;379(4):352-362.
BioCryst. Prescribing information Orladeyo. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo. Accessed August 21, 2021.
Manning ME, Kashkin JM. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: review of phase II and III studies. Allergy Asthma Proc. 2021;42(4):274-282.
Farkas H, Stobiecki M, Peter J, et al. Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study. Clin Transl Allergy. 2021;11(4):e12035.
Banerji A, Anderson J, Johnston DT. Optimal management of hereditary angioedema: shared decision-making. J Asthma Allergy. 2021;14:119-125.
Valerieva A, Caccia S, Cicardi M. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema. Expert Rev Clin Immunol. 2018;14(9):707-718.
Castaldo AJ, Jervelund C, Corcoran D, Boysen HB, Christiansen SC, Zuraw BL. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema. Allergy Asthma Proc. 2021;42(2):108-117.
Mendivil J, Murphy R, de la Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16(1):94.
Agostoni A, Cicardi M, Martignoni GC, Bergamaschini L, Marasini B. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol. 1980;65(1):75-79.
Blackmore WP. Danazol in the treatment of hereditary angio-neurotic oedema. J Int Med Res. 1977;5(Suppl 3):38-43.
Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153-161.
Farkas H, Czaller I, Csuka D, et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol. 2010;66(4):419-426.
Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295(26):1444-1448.
Fust G, Farkas H, Csuka D, Varga L, Bork K. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest. 2011;41(3):256-262.
Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion. 2009;49(9):1987-1995.
Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol. 1981;68(3):181-187.
Zotter Z, Veszeli N, Csuka D, Varga L, Farkas H. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet J Rare Dis. 2014;9:205.
Bouillet L, Gompel A. Hereditary angioedema in women: specific challenges. Immunol Allergy Clin North Am. 2013;33(4):505-511.
Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol. 1992;99(3):212-215.
Wentz AC. Adverse effects of danazol in pregnancy. Ann Intern Med. 1982;96(5):672-673.
Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114(4):281-288. e287.
Stankovic I, Vlahovic-Stipac A, Putnikovic B, Cvetkovic Z, Neskovic AN. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. Clin Ther. 2010;32(5):909-914.
Johnston DT, Henry Li H, Craig TJ, et al. Androgen use in hereditary angioedema: a critical appraisal and approaches to transitioning from androgens to other therapies. Allergy Asthma Proc. 2021;42(1):22-29.
Craig TJ. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc. 2008;29(3):225-231.
Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med. 1977;86(3):306-308.
Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet. 1999;353(9158):1066-1067.
Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol. 2002;36(5):707-709.
Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147-157.
Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003;24(4):523-538.
Wu YS, Chen SD, Li TH, Liu JS, Lan MY, Chang YY. Intracranial hypertension associated with danazol withdrawal: a case report. Acta Neurol Taiwan. 2007;16(3):173-176.
Lundh B, Laurell AB, Wetterqvist H, White T, Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin Exp Immunol. 1968;3(7):733-745.
Gwynn CM. Therapy in hereditary angioneurotic oedema. Arch Dis Child. 1974;49(8):636-640.
Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand. 1972;192(4):293-298.
Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287(9):452-454.
Lundh B. Tranexamic acid in hereditary angioneurotic edema-a progress report. N Engl J Med. 1973;288(1):53.
Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308-320.
Farkas H, Harmat G, Fust G, Varga L, Visy B. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002;13(3):153-161.
Katelaris CH, Lima H, Marsland A, Weller K, Shah A, Waserman S. How to measure disease activity, impact, and control in patients with recurrent wheals, angioedema, or both. J Allergy Clin Immunol Pract. 2021;9(6):2151-2157.
Balla Z, Ignacz B, Varga L, Kohalmi KV, Farkas H. How angioedema quality of life questionnaire can help physicians in treating C1-inhibitor deficiency patients? Clin Rev Allergy Immunol. 2021;61(1):50-59.
Bork K, Anderson JT, Caballero T, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17(1):40.
Kulthanan K, Chularojanamontri L, Rujitharanawong C, Weerasubpong P, Weller K, Maurer M. Angioedema activity score (AAS): a valid and reliable tool to use in asian patients. Biomed Res Int. 2019;2019:9157895.
Kulthanan K, Chularojanamontri L, Rujitharanawong C, Weerasubpong P, Maurer M, Weller K. Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change. Health Qual Life Outcomes. 2019;17(1):160.
Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front Med (Lausanne). 2017;4:212.
Nordenfelt P, Nilsson M, Lindfors A, Wahlgren CF, Bjorkander J. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. Allergy Asthma Proc. 2017;38(6):447-455.
Riedl MA, Aygoren-Pursun E, Baker J, et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy. 2018;73(9):1871-1880.
Aygoren-Pursun E, Magerl M, Graff J, et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. J Allergy Clin Immunol. 2016;138(3):934-936. e935.
Fukunaga A, Morita E, Miyagi T, et al. Efficacy, pharmacokinetics, pharmacodynamics, and safety of intravenous C1 inhibitor for long-term prophylaxis and treatment of breakthrough attacks in Japanese subjects with hereditary angioedema: a phase 3 open-label study. Arerugi. 2020;69(3):192-203.
Squeglia V, Barbarino A, Bova M, et al. High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study. Orphanet J Rare Dis. 2016;11(1):133.
Bonnekoh H, Ellrich A, Hawro T, Weller K, Maurer M, Magerl M. Hereditary angioedema due to C1-INH deficiency: age of onset and delay in diagnosis in Germany. In Global Forum on Hereditary Angioedema, Warsaw, Poland: Dpt. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin; 2016.
Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10):1229-1235.
Christiansen SC, Davis DK, Castaldo AJ, Zuraw BL. Pediatric hereditary angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr (Phila). 2016;55(10):935-942.
Martinez-Saguer I, Graff J, Rusicke E, Aygören-Pürsün E, Klingebiel T, Kreuz W. Does early clinical manifestation of hereditary angioedema (HAE) influence the clinical course of the disease? J Allergy Clin Immun. 2013;131(2):AB30.
Martinez-Saguer I, Farkas H. Erythema marginatum as an early symptom of hereditary angioedema: case report of 2 newborns. Pediatrics. 2016;137(2):e20152411.
Nguyen A, Zuraw BL, Christiansen SC. Contact system activation during erythema marginatum in hereditary angioedema. Ann Allergy Asthma Immunol. 2020;124(4):394-395. e391.
Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol. 2005;16(4):288-294.
Caballero T. Angio-oedema due to hereditary C1 inhibitor deficiency in children. Allergol Immunopathol (Madr). 2013;41(1):45-53.
Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;6(1):18.
Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300-313.
Frank MM, Zuraw B, Banerji A, et al. Management of children with hereditary angioedema due to C1 inhibitor deficiency. Pediatrics. 2016;138(5):e20160575.
Wahn V, Aberer W, Aygoren-Pursun E, et al. Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries. Pediatr Allergy Immunol. 2020;31(8):974-989.
Aabom A, Andersen KE, Fagerberg C, Fisker N, Jakobsen MA, Bygum A. Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema. Orphanet J Rare Dis. 2017;12(1):55.
Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35(2):184-187.
Yokoyama K, Horiuchi T, Hashimura C, Yoshida A. A novel C1 inhibitor gene mutation in a family with hereditary angioedema: use of genetic analysis to facilitate early diagnosis. Allergol Int. 2020;69(1):148-149.
Grumach AS, Ceccon ME, Rutz R, Fertig A, Kirschfink M. Complement profile in neonates of different gestational ages. Scand J Immunol. 2014;79(4):276-281.
Spath PJ, Angioedema Wuthrich B. A review on the acquired, allergic or non-allergic, and the hereditary forms. Recenti Prog Med. 1990;81(7-8):513-531.
Speletas M, Szilagyi A, Psarros F, et al. Hereditary angioedema: molecular and clinical differences among European populations. J Allergy Clin Immunol. 2015;135(2):570-573.
Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol. 2008;45(13):3536-3544.
Farkas H, Reshef A, Aberer W, et al. Treatment effect and safety of icatibant in pediatric patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2017;5(6):1671-1678. e1672.
Lumry W, Soteres D, Gower R, et al. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema. Pediatr Allergy Immunol. 2015;26(7):674-680.
Farkas H, Csuka D, Zotter Z, et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J Allergy Clin Immunol. 2013;131(3):909-911.
Farkas H, Csuka D, Zotter Z, Varga L, Fust G. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol. 2013;131(2):579-582. e571-572.
Wahn V, Aberer W, Eberl W, et al. Hereditary angioedema (HAE) in children and adolescents-a consensus on therapeutic strategies. Eur J Pediatr. 2012;171:1339-1348.
Caballero T, Maurer M, Longhurst HJ, et al. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol. 2016;26(6):383-386.
Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484. e481-484.
Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013;43(4):475-482.
Zotter Z, Csuka D, Szabo E, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9:44.
Farkas H, Varga L, Szeplaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120(3):e713-e722.
Czaller I, Visy B, Csuka D, Fust G, Toth F, Farkas H. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44-49.
Martinez-Saguer I, Rusicke E, Aygoren-Pursun E, Heller C, Klingebiel T, Kreuz W. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(2):131. e131-137.
Gonzalez-Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2016;26(3):161-167.
Satomura A, Fujita T, Nakayama T. Comparison of the frequency of angioedema attack, before and during pregnancy, in a patient with type I hereditary angioedema. Intern Med. 2018;57(5):751-755.
Sankrithi P, Shah K, Bernabe CC. Pregnancy-induced exacerbation of hereditary angioedema in a multiparous caucasian female. Cureus. 2020;12(5):e8006.
Caballero T, Canabal J, Rivero-Paparoni D, Cabanas R. Management of hereditary angioedema in pregnant women: a review. Int J Womens Health. 2014;6:839-848.
Halbmayer WM, Hopmeier P, Mannhalter C, et al. C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost. 1991;65(2):134-138.
Ogston D, Walker J, Campbell DM. C1 inactivator level in pregnancy. Thromb Res. 1981;23(4-5):453-455.
Baker JW, Craig TJ, Riedl MA, et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc. 2013;34(2):162-169.
Fox J, Vegh AB, Martinez-Saguer I, et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc. 2017;38(3):216-221.
Brooks JP, Radojicic C, Riedl MA, Newcomer SD, Banerji A, Hsu FI. Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review. J Allergy Clin Immunol Pract. 2020;8(6):1875-1880. e1873.
Kardum Z, Prus V, Milas Ahic J, Kardum D. Successful treatment with Cinryze(R) replacement therapy of a pregnant patient with hereditary angioedema: a case report. J Med Case Rep. 2021;15(1):20.
Moldovan D, Bernstein JA, Hakl R, et al. Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. J Allergy Clin Immunol Pract. 2019;7(8):2938-2940.
Kaminsky LW, Kelbel T, Ansary F, Craig T. Multiple doses of icatibant used during pregnancy. Allergy Rhinol (Providence). 2017;8(3):178-181.
Farkas H, Kohalmi KV, Veszeli N, Toth F, Varga L. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res. 2016;42(8):1026-1028.
Zanichelli A, Mansi M, Periti G. Icatibant exposure during pregnancy in a patient with hereditary angioedema. J Investig Allergol Clin Immunol. 2015;25(6):447-449.
Galan HL, Reedy MB, Starr J, Knight AB. Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. J Reprod Med. 1996;41(7):541-544.
Nathani F, Sullivan H, Churchill D. Pregnancy and C1 esterase inhibitor deficiency: a successful outcome. Arch Gynecol Obstet. 2006;274(6):381-384.
Caliskaner Z, Ozturk S, Gulec M, Dede M, Erel F, Karaayvaz M. A successful pregnancy and uncomplicated labor with C1INH concentrate prophylaxis in a patient with hereditary angioedema. Allergol Immunopathol (Madr). 2007;35(3):117-119.
Gorman PJ. Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate. Can Fam Physician Med Fam Can. 2008;54(3):365-366.
Farkas H, Csuka D, Toth F, Koszegi L, Varga L. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):366-367.
Bouillet L, Lehmann A, Gompel A, et al. Hereditary angioedema treatments: recommendations from the French national center for angioedema (Bordeaux consensus 2014). Presse Med. 2015;44(5):526-532.
Gilad O, Merlob P, Stahl B, Klinger G. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med. 2014;9(8):407-410.
Katelaris CH. Self-management plans in patients with hereditary angioedema: strategies, outcomes and integration into clinical care. J Asthma Allergy. 2020;13:153-158.
Longhurst H. Optimum use of acute treatments for hereditary angioedema: evidence-based expert consensus. Front Med (Lausanne). 2017;4:245.
Paige D, Maina N, Anderson JT. Hereditary angioedema: Comprehensive management plans and patient support. Allergy Asthma Proc. 2020;41(Suppl 1):S38-S42.
Riedl MA. Creating a comprehensive treatment plan for hereditary angioedema. Immunol Allergy Clin North Am. 2013;33(4):471-485.
Williams AH, Craig TJ. Perioperative management for patients with hereditary angioedema. Allergy Rhinol (Providence). 2015;6(1):50-55.
Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci. 2003;29(3):239-245.
Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458-467.
Banerji A, Bas M, Bernstein JA, et al. Expert perspectives on hereditary angioedema: key areas for advancements in care across the patient journey. Allergy Rhinol (Providence). 2016;7(3):172-181.
Banerji A, Busse P, Christiansen SC, et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc. 2015;36(3):213-217.
Boccon-Gibod I. Hereditary angioedema: treatment and educational therapeutic program. Presse Med. 2015;44(1):78-88.
Nasr IH, Manson AL, Al Wahshi HA, Longhurst HJ. Optimizing hereditary angioedema management through tailored treatment approaches. Expert Rev Clin Immunol. 2016;12(1):19-31.
Aygoren-Pursun E, Bork K. Hereditary angioedema. Der Internist. 2019;60(9):987-995.
Aygoren-Pursun E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol. 2010;6(1):21.
Gill P, Betschel SD. The clinical evaluation of angioedema. Immunol Allergy Clin North Am. 2017;37(3):449-466.
Manson AL, Price A, Dempster J, et al. In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency. Clin Exp Immunol. 2013;173(1):1-7.
Krack AT, Bernstein JA, Ruddy RM. Recognition, evaluation, and management of pediatric hereditary angioedema. Pediatr Emerg Care. 2021;37(4):218-223.
Maurer M, Aberer W, Agondi R, et al. Definition, aims, and implementation of GA(2) LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy. 2020;75(8):2115-2123.
Serpa FS, Mansour E, Aun MV, et al. Hereditary angioedema: how to approach it at the emergency department? Einstein (Sao Paulo). 2021;19:eRW5498.
Pines JM, Poarch K, Hughes S. Recognition and differential diagnosis of hereditary angioedema in the emergency department. J Emerg Med. 2021;60(1):35-43.
Hahn J, Bock B, Muth CM, et al. The ulm emergency algorithm for the acute treatment of drug-induced, bradykinin-mediated angioedema. Med Klin Intensivmed Notfmed. 2019;114(8):708-716.
Long BJ, Koyfman A, Gottlieb M. Evaluation and management of angioedema in the emergency department. West J Emerg Med. 2019;20(4):587-600.
Cicardi M, Craig TJ, Martinez-Saguer I, Hebert J, Longhurst HJ. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol. 2013;161(Suppl 1):3-9.
Muhlberg H, Ettl N, Magerl M. An analysis of the teaching of intravenous self-administration in patients with hereditary angio-oedema. Clin Exp Dermatol. 2016;41(4):366-371.
Zanichelli A, Azin GM, Cristina F, Vacchini R, Caballero T. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert(R)) in patients with hereditary angioedema: the SABHA study. Orphanet J Rare Dis. 2018;13(1):51.
Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy. 2014;69(3):305-314.
Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Heller C, Klingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion. 2012;52(1):100-107.
Bernstein JA, Riedl M, Zacek L, Shapiro RS. Facilitating home-based treatment of hereditary angioedema. Allergy Asthma Proc. 2015;36(2):92-99.
Bygum A. Hereditary angioedema - consequences of a new treatment paradigm in Denmark. Acta Derm Venereol. 2014;94(4):436-441.
Li HH. Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance. Patient Prefer Adherence. 2016;10:1727-1737.
Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL. Safety and efficacy of physician-supervised self-managed c1 inhibitor replacement therapy. Int Arch Allergy Immunol. 2012;157(4):417-424.
Tuong LA, Olivieri K, Craig TJ. Barriers to self-administered therapy for hereditary angioedema. Allergy Asthma Proc. 2014;35(3):250-254.
Symons C, Rossi O, Magerl M, Andritschke K. Practical approach to self-administration of intravenous C1-INH concentrate: a nursing perspective. Int Arch Allergy Immunol. 2013;161(Suppl 1):17-20.
Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(4):314-320.
Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31(6):511-519.
Abdel-Karim O, Dizdarevic A, Bygum A. Hereditary angioedema: children should be considered for training in self-administration. Pediatr Dermatol. 2014;31(6):e132-e135.
Craig T. Triggers and short-term prophylaxis in patients with hereditary angioedema. Allergy Asthma Proc. 2020;41(Suppl 1):S30-S34.
Steiner UC, Kolliker L, Weber-Chrysochoou C, et al. Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema. Orphanet J Rare Dis. 2018;13(1):90.
Teranishi R, Makino Y, Amano E, Shibuya H, Okada T. Perioperative management of a patient with hereditary angioedema: a case report. Masui. 2015;64(4):441-443.
Visy B, Fust G, Bygum A, et al. Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter. 2007;12(3):251-257.
Zotter Z, Veszeli N, Kohalmi KV, et al. Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1-inhibitor deficiency. Allergy. 2016;71(12):1791-1793.
Belbezier A, Arnaud M, Boccon-Gibod I, et al. COVID-19 as a trigger of acute attacks in people with hereditary angioedema. Clin Exp Allergy. 2021;51(7):947-950.
Can Bostan O, Tuncay G, Damadoglu E, Karakaya G, Kalyoncu AF. Effect of COVID-19 on hereditary angioedema activity and quality of life. Allergy Asthma Proc. 2021;42(5):403-408.
Grumach AS, Goudouris E, Dortas Junior S, et al. COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2021;9(1):508-510.
Mete Gokmen N, Kuman Tuncel O, Bogatekin G, et al. Psychiatric and clinical characteristics of hereditary angioedema patients who experienced attacks during COVID-19. J Investig Allergol Clin Immunol. 2021;31(4):356-357.
Fijen LM, Levi M, Cohn DM. COVID-19 vaccination and the risk of swellings in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(11):4156-4158.
Araujo-Simoes J, Boanova AGP, Constantino-Silva RN, et al. The challenges in the follow-up and treatment of brazilian children with hereditary angioedema. Int Arch Allergy Immunol. 2021;182(7):585-591.
Johnston DT, Smith RC. Hereditary angioedema: Special considerations in children. Allergy Asthma Proc. 2020;41(Suppl 1):S43-S46.
Valle SOR, Alonso MLO, Tortora RP, Abe AT, Levy SAP, Dortas SD Jr. Hereditary angioedema: Screening of first-degree blood relatives and earlier diagnosis. Allergy Asthma Proc. 2019;40(4):279-281.